Atlas Trials

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Clinical trial NCT06255262 · UNKNOWN

Trial details

NCT number
NCT06255262
Sponsor
China Medical University, China
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Biliary Tract Cancer
Start date
2024-02-15
Primary completion
2025-10-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.